New Delhi: The Indian Council of Medical Research (ICMR) is planning to test the efficacy of two medicines — Metformin and Bedaquiline Delaminate — for tackling the drug-resistant tuberculosis.
Metformin is widely used to treat type-II diabetes. ICMR now plans a clinical trial to examine its effectiveness in fighting the TB microbe following encouraging scientific results from Indian biologists, reports Deccan Herald.
Bedaquiline, which received the US Food and Drug Administration’s approval in 2012 for the treatment of drug-resistant TB cases, is yet to be used in India’s public-funded national TB control programme.
The Metformin trial is expected to start in a couple of months, while the Bedaquiline trial may take about six months to kick off, according to ICMR director general Dr Soumya Swaminathan.